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A B S T R A C T
The purpose of the study was to investigate possible differences in the survival and outcome of malignant brain
glioma patients when treated by two different methods of surgery. During a 3-year period, 32 glioma patients underwent
surgery and oncological protocol afterwards. The patients were divided into two groups according to the surgical method
applied. The case group comprised 11 patients in whom a stereotactic biopsy was performed, while the control group con-
sisted of 21 patients who were operated on by radical surgery (craniotomy and maximal reduction of the tumor mass). All
survived patients were clinically examined at follow-ups (one year and 2 years following the surgery). The monitored
variables for both groups were the tumor pathohistology (the tumor type), the survival rate (time between surgery and fol-
low-up), and the outcome assessed by The Extended Glasgow Outcome Scale. Data statistical analysis was done to com-
pare various investigated variables in two different groups of patients. The majority of patients treated by a stereotactic
biopsy survived for more than 2 years following the procedure. The great part of patients treated by radical surgery died
or was severely disabled at follow-up examination. The survival and outcome for the patients in whom a stereotactic bi-
opsy was performed were notably better comparing to the patients who were treated by radical surgery. Consequently, it
appears that a stereotactic biopsy is surgical option for primary treatment of selected patients with malignant brain
glioma when the survival and quality of life are concerned.
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Introduction
Gliomas are a heterogeneous group of neoplasms that
comprise the majority of tumors originating in the cen-
tral nervous system1. A number of surgical options are
available for patients suffering from different grade of
malignant glioma. The principal objective of any man-
agement is to advance both the duration of life and qual-
ity of survival.
Typically, the standard treatment for these tumors is
a surgery followed by radiation and chemotherapy. Sur-
gery and/or tumor tissue biopsy are required for a defi-
nite pathohistological diagnosis, which will dictate suc-
ceeding therapy preferences. Maximal surgical tumor
resection, advocated by some authors, is a well known
way to improve glioma prognosis1. However, if for vari-
ous reasons a glioma cannot be radically removed, the
method of choice remains a stereotactic biopsy to verify
tumor cell histology, which facilitates the proper treat-
ment choice. Nevertheless, prognostic factors for the tre-
atment of malignant brain glioma have yet to be defi-
nitely identified2. Therefore, examining the impact of
patient selection on the survival and outcome is rather
important3.
The purpose of this study is to investigate whether
there are any differences in the survival and outcome of
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malignant brain glioma when treated by two different
methods of surgery (radical open surgery vs. stereotactic
biopsy).
Patients and Methods
During a 3-year period, 32 patients with different
types of malignant brain gliomas underwent surgery at
the Neurosurgery Unit of the Clinic for Surgery, Univer-
sity Hospital Mostar, Bosnia and Herzegovina, and were
treated by oncological protocol afterwards (radiation and
chemotherapy). The average age of the patients was
62.5±SD13.9 years.
The patients were divided into two groups according
to the surgical method applied. The case group of 11 pa-
tients consisted of 9 (81.8%) males and 2 (18.2%) females
with an average age of 61.2 years. They underwent a
stereotactic biopsy as a method of primary surgical treat-
ment. The patients in whom a craniotomy and maximal
reduction of the tumor mass were performed comprised
the control group of 21 patients (radical surgery group),
consisting of 13 (61.9%) males and 8 (38.1%) females
with an average age of 62.3 years.
All survived patients were clinically examined at fol-
low-ups twice, one year and 2 years after the surgery. The
observed variables for both groups of patients were the
tumor pathohistology (the tumor type), the survival pe-
riod (the time between surgery and follow-up), and the
outcome (the quality of life) assessed by The Extended
Glasgow Outcome Scale (GOSE)4,5.
Data statistical analysis was carried out to compute
the results and compare various investigated prognostic
variables in two different groups of patients. c2-test and
Fisher’s Exact Test were used to analyze the difference
in frequency variances between the case and the control
group. The level of significance was set at p<0.05. Com-
mercially available software (SPSS for Windows, release
9.0.0, by SPSS Inc., Chicago, Illinois, USA) was utilized
for data processing.
Results
Nine out of 11 (81.8%) patients in the case group
(stereotactic biopsy) survived, while 2 patients died. The
fatality rate for the case group was 18.2%. The tumor
was located above the tentorium, in the frontal, parietal,
and occipital cerebral lobe in 2 patients each (18.2%), in
the temporal lobe in one patient (9.1%), in both the tem-
poral and occipital lobes in 2 (18.2%), and in the mid-
brain in 2 patients (18.2%; Table 1).
Regarding the tumor type (pathohistological tumor
tissue diagnostics), glioblastoma muliforme was recorded
in 5 (45.5%) patients of the case group, astrocytoma and
ependymoma were recorded in 2 cases each (18.2%),
while oligodendroglioma and mixed glioma were noticed
in one patient each (9.1%; Table 2).
Six patients (54.5%) were additionally operated on by
open surgery due to continued tumor growth following a
stereotactic procedure. Two patients from the case group
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TABLE 1
DiSTRIBUTION OF PATIENTS FROM BOTH GROUPS AC-
CORDING TO TUMOR LOCALIZATION
Tumor localization





Frontal lobe 3 (14.3) 2 (18.2)
Parietal lobe 3 (14.3) 2 (18.2)
Temporal lobe 5 (23.8) 1 (9.1)
Occipital lobe 2 (9.5) 2 (18.2)
Frontal and parietal lobes 4 (19.0) 0
Parietal and temporal lobes 2 (9.5) 0
Temporal and occipital lobes 1 (4.8) 2 (18.2)
Midbrain 1 (4.8) 2 (18.2)














Fig. 1. Comparison of the outcome between the case and control
group.
TABLE 2
DiSTRIBUTION OF PATIENTS FROM BOTH GROUPS AC-
CORDING TO TUMOR PATHOHISTOLOGY
Tumor type





Glioblastoma multiforme 10 (47.6) 5 (45.5)
Astrocytoma 2 (18.2) 2 (18.2)
Epedymoma 2 (18.2) 2 (18.2)
Oligodendroglioma 5 (23.8) 1 (9.1)
Mixed glioma 2 (18.2) 1 (9.1)
Total 21 (100.0) 11 (100.0)
c2=1.709; df=4; p=0.789
died and one patient (11.1%) among the survived was
GOSE I–IV (severely disabled), 5 patients (55.5%) were
GOSE V–VII (mild to moderate disability), and 3 pa-
tients (33.3%) were GOSE VIII (full recovery). In 8
(88.9%) patients a satisfactory outcome was recorded
(GOSE V–VIII) (Figures 1 and 3). In eight out of 9 pa-
tients (88.9%) from the case group, the survival for more
than 2 years was recorded, while one patient (11.1%) sur-
vived less than 2 years (Figures 2 and 4).
In the control group (radical surgery), 9 out of 21
(42.9%) patients survived and 12 patients succumbed.
The control group fatality rate was 57.1%. All tumors
were located supratentorially, in the temporal cerebral
lobe in 5 (23.8%) patients, in both the frontal and pari-
etal lobes in 4 (19.1%), in the frontal and parietal lobes in
3 (14.3%) patients each, in the occipital lobe in 2 (9.5%),
in both the parietal and temporal in 2 (9.5%), and in both
the temporal and occipital lobes, and in the midbrain in 1
case each (4.8%; Table 1).
A glioblastoma muliforme was recorded by patho-
histological tumor tissue diagnostics in 10 (47.6%) pati-
ents of the control group, oligodendroglioma in 5 (23.8%),
and astrocytoma, ependymoma and mixed glioma in 2
patients each (9.5%; Table 2). Five patients (23.8%) from
the control group were re-operated on due to continued
tumor growth.
In the control group 12 patients died and 5 (55.6%)
among the survived patients were GOSE I–IV at the fol-
low-ups. Three patients (33.3%) were GOSE V–VII, and
one (11.1%) was GOSE VIII. A satisfactory outcome was
recorded in 4 (44.4%) patients (GOSE V–VIII) (Figures 1
and 3). The survival for more than 2 years was recorded
in 4 out of 9 (44.4%) patients, while 5 (55.5%) patients
survived less than 2 years after surgery (Figures 2 and 4).
There were no statistically significant differences in
variables between the case and control group regarding
the tumor localization (c2=7.324; df=7; p=0.396) and the
tumor type (pathohistology) (c2=1.709; df=4; p=0.789),
indicating that the investigated samples were homoge-
neous and that the groups were properly selected (Tables
1, 2). However, when the tumor pathohistology was cor-
related for the entire sample of all 32 patients, a statisti-


























Fig. 3. Satisfactory outcome in the patients who survived surgery.
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CASE GROUP 2 YRS
CONTROL GROUP 2 YRS
Fig. 4. 2-year survival in both groups of the patients.
TABLE 3
DISTRIBUTION OF ALL PATIENTS ACCORDING TO TUMOR
PATHOHISTOLOGY
Tumor type No (%) of patients




Mixed glioma 3 (9.4)
Total 32 (100.0)
c2=15.188; df=4; p=0.004
cally highly significant difference between the number of
high-grade glioma patients and the number of those with
other tumor types was observed (c2=15.188; df=4;
p=0.004),t demonstrating that glioblastoma multiforme
was by far the most frequent tumor type that was found
in 15 out of 32 (46.9%) patients in our series (Table 3).
When the outcome assessed by The Extended Glas-
gow Coma Scale of the case group was compared to that
of the control group, a statistically significant difference
between the groups was observed for a bad outcome
(GOSE I–IV) in favor of the survived patients from the
case group (c2=4.000; df=1; p=0.046 Fisher’s Exact
Test) (Table 4). However, no statistical difference be-
tween the groups was observed for a satisfactory out-
come (GOSE V–VIII) (c2=0.900; df=1; p=0.343 Fisher’s
Exact Test).
When the survival rate of the case group was com-
pared to that of the control group, a statistically signifi-
cant difference between the groups was observed for a
2-year survival period in favor of the patients from the
case group (c2=4.000; df=1; p=0.046 Fisher’s Exact
Test; Table 5).
Discussion
The glioma treatment options and survival odds are
associated with the tumor type, size and location, as well
as the patient’s age. The goal of glioma surgery is to re-
move as much of the tumor as possible, while minimizing
damage to healthy tissue. However, uncertainty still ex-
ists about the adequate treatment of adult patients with
unresectable, primary, biopsy-proven high-grade glioma6.
The majority of the patients from both groups in our se-
ries were middle aged men in whom the tumor was lo-
cated supratentorially, mostly at the frontal, parietal and
temporal cerebral lobes (Table 1). Pathohistologically,
high-grade glioma (glioblastoma mulitiforme) was the
most frequent tumor type found (Tables 2 and 3).
Since an appropriate tumor treatment depends upon
precise morphological diagnosis7, we have preferred a
stereotactic biopsy as a primary surgical option for se-
lected malignant brain glioma patients. In view of this,
computed tomography-guided stereotactic brain tumor
biopsy proved to be an effective, feasible, reliable and rel-
atively safe method associated with a low likelihood of
postbiopsy hemorrhage, which can even be performed as
an outpatient day-surgery procedure8–11. While some au-
thors have stressed that the method may be inaccurate in
ensuring a correct pathohistological diagnosis12, we sup-
port the standpoint that a stereotactic biopsy can usually
provide accurate tumor material which is sufficient eno-
ugh for further clinical management guiding subsequent
therapy7,13–15. Therefore, it should be employed to direct
glioma therapy where complete excision is not possible or
when diagnostic questions arise16. Usually, the rationale
cited for performing a stereotactic biopsy was the tumor
localization, preferably in eloquent or near-eloquent brain
areas12, and the most frequently established histopatho-
logical diagnosis was a glioblastoma multiforme14.
This background characterizes the crucial idea of this
study, the main hypothesis of which is that a sterotactic
biopsy represents less radical surgery, having some ad-
vantages over open surgery when the outcome and sur-
vival for selected brain giloma patients are concerned.
In view of this, a statistically significant difference be-
tween the case and control group of our patients was ob-
served for a bad outcome (GOSE I–IV) in favor of the pa-
tients who were treated by a stereotactic biopsy (p<0.05)
(Tables 3 and 4, Figures 1 and 2).
Prognostic glioma factors that predict overall survival
rate include young age, pilocytic histology, gross total re-
section, and small preoperative tumor volumes17,18. At
the same time, gross total tumor resection was associ-
ated with significantly improved survival rate compared
to tumor biopsy only19. On the contrary, some studies
evaluating low-grade glioma suggest that no survival
benefit was related to the initial tumor resection when
compared to biopsy20. Considering this, a statistically sig-
nificant difference between the case and control group
was observed for a 2-year survival period in favor of the
patients who were treated by a stereotactic biopsy in our
series (p<0.05) (Tables 3 and 4, Figures 3 and 4).
Conclusion
The majority of patients (88.9%) in whom a ste-
reotactic biopsy was performed survived for a two-year
period and recovered well (GOSE V–VIII). Most of those
treated by radical surgery succumbed (57.1%) or were se-
verely disabled (55.6%) at follow-ups (GOSE I–IV). The
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TABLE 4
DiSTRIBUTION OF SURVIVED PATIENTS WITH UNFAVORABLE
OUTCOME (GOSE I–IV)
GOSE I–IV




Yes 5 (55.6) 1 (11.1)
No 4 (44.4) 8 (88.9)
Total 9 (100) 9 (100)
c2=4.000; df=1; p=0.046 Fisher’s Exact Test
TABLE 5
DISTRIBUTION OF SURVIVED PATIENTS ACCORDING TO
LENGTH OF SURVIVAl
Survival period




<2 yrs 5 (55.6) 1 (11.1)
2 yrs 4 (44.4) 8 (88.9)
Total 9 (100) 9 (100)
c2=4.000; df=1; p=0.046 Fisher’s Exact Test
survival rate was by far higher and the outcome was con-
siderably better in the patients from a stereotactic biopsy
group compared to those from radical surgery group.
Considering the results of this study, it appears that a
stereotactic biopsy is well justified as a surgical method
of choice for the primary malignant brain glioma treat-
ment concerning the survival and the quality of life of se-
lected patients. Eventually, it is necessary to remind of a
particular limitation of this study that occurs from its
retrospective character and relatively small number of
patients. Therefore, supplementary prospective investi-
gations are required to support these findings.
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VRIJEDNOST STEREOTAKSIJSKE BIOPSIJE U POBOLJ[ANJU STOPE PRE@IVLJAVANJA I
KVALITETE @IVOTA BOLESNIKA S MALIGNIM GLIOMIMA MOZGA
S A @ E T A K
Cilj ovoga rada bio je istra`iti mogu}e razlike u stopi pre`ivljavanja i uspje{nosti lije~enja bolesnika s malignim
gliomima mozga lije~enih dvama razli~itim kirur{kim metodama. Tijekom trogodi{njega razdoblja, 32 su bolesnika s
gliomima mozga kirur{ki lije~ena, nakon ~ega je proveden onkolo{ki terapijski protokol. Bolesnici su bili podijeljeni u
dvije skupine, ovisno o primijenjenoj metodi kirur{koga lije~enja. Oglednu skupinu ~inilo je 11 bolesnika u kojih je
u~injena stereotaksijska biopsija, a kontrolnu skupinu sa~injavao je 21 radikalno operirani bolesnik (kraniotomija i
maksimalna redukcija tumorskoga tkiva). Svi su pre`ivjeli bolesnici klini~ki ispitivani na kontrolnim pregledima (u
razdoblju od godinu dana i 2 godine nakon kirur{koga lije~enja). Promatrane varijable u obje skupine bile su tumorska
patohistologija (tip tumora), stopa pre`ivljavanja (vrijeme izme|u operacije i kontrolnoga pregleda), te uspje{nost lije-
~enja prosu|ena pomo}u pro{irene glazgovske ljestvice uspje{nosti lije~enja (The Extended Glasgow Outcome Scale).
Statisti~ka analiza podataka provedena je radi usporedbe razli~itih istra`ivanih varijabli iz obje skupine bolesnika.
Ve}ina bolesnika u kojih je u~injena stereotaksijska biopsija pre`ivjela je zahvat du`e od 2 godine, dok je ve}ina radikal-
no operiranih bolesnika umrla ili je bila te{ko onesposobljena na kontrolnom pregledu. Stopa pre`ivljavanja i uspje-
{nost lije~enja u bolesnika operiranih metodom stereotaksijske biopsije bili su znatno bolji u usporedbi s onima u radi-
kalno operiranih bolesnika. Sukladno tomu, ~ini se kako je stereotaksijska biopsija kirur{ka metoda izbora primarnoga
lije~enja selekcioniranih bolesnika s malignim gliomima mozga kada je u pitanju pre`ivljavanje i kvaliteta `ivota ovak-
vih bolesnika.
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